AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec
RIME Therapeutics, a Montreal-based biotech startup, has been awarded the AbbVie Biotech Innovators Award, providing a year of laboratory and office space at the adMare Innovation Centre. The award supports RIME's development of a peptide-based drug discovery platform for inflammation and immunology.
AbbVie and adMare BioInnovations have recognized RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award. RIME Therapeutics is a Montreal-based startup focused on developing a peptide-based drug discovery platform for inflammation and immunology. The award provides a year of laboratory and office space at the adMare Innovation Centre in Montreal, including access to shared equipment and services, as well as mentorship from AbbVie's scientific and business leaders. RIME Therapeutics was founded in 2025 and impressed the selection committee with its disruptive approach to drug discovery. The company aims to address novel T cell biology with broad therapeutic applicability. The AbbVie Biotech Innovators Award supports early-stage biotech companies with potential to generate transformational therapies in areas aligning with AbbVie's therapeutic focus.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.